Clinical Trials
5 trialsNCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02521051 2025-05-13
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT03445000 2025-04-08
ALERT-lung
ETOP IBCSG Partners Foundation
Phase 2 Terminated
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT03131206 2021-09-27
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Dana-Farber Cancer Institute
Phase 1/2 Terminated